カテゴリ： GlobalData, アメリカ, 企業調査

University of California：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：University of California - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10503
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：173
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
University of California is a public research university system that offers educational and research services. The university’ services include research and teaching services, graduate, undergraduate and postgraduate courses, doctoral programs and courses, master’s programs, degree programs, bachelors programs, extension courses, student exchange and transfer services. It also provides laboratory services, library services, museums, concert halls, art galleries, botanical gardens, observatories and marine centers, academic resources, continuing education courses, agricultural advice and educational programs. University of California offers faculty grant programs, fellowship programs, and faculty-led partnerships and research collaborations, among others. The university provides its services through its campuses, facilities and departments. University of California is headquartered in Bakersfield, California, the US.

University of California – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 9
University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
University of California, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
University of California, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
University of California, Medical Devices Deals, 2012 to YTD 2018 15
University of California, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
University of California, Pharmaceuticals & Healthcare, Deal Details 26
Venture Financing 26
DNAlite Therapeutics Raises USD1.5 Million in Seed Financing 26
Private Equity 28
Allogene Therapeutics Raises USD120 Million in Private Financing 28
Partnerships 30
Akili Interactive Enters into Licensing Agreement with University of California 30
PharmaResearch Products Enters into Agreement with University of California 31
Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 32
InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 33
Helperby Therapeutics Enters into Collaboration Agreement with University of California Los Angeles 34
OncoSec Medical Enters into Research Agreement with University of California 35
Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 36
Protagen Enters into Agreement with University of California, San Francisco 37
INSYS Therapeutics Expands Agreement with University of California San Diego 38
Clerisy Enters into Partnership with University of California 39
Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 40
MYOS RENS Technology Enters into Research Agreement with University Of California Berkley 41
Fate Therapeutics Enters into Partnership with University of California San Diego 42
Apexigen Enters into Agreement with University of California San Francisco 43
Strata Oncology Enters into Agreement with University of California 44
Novartis Enters into Agreement with University of California 45
BrainStorm Cell Therapeutics Enters into Agreement with University of California Irvine Medical Center 46
ShangPharma Innovation Enters into Partnership with the University of California San Francisco 47
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 48
Xynomic Pharma Enters into Agreement with University of California San Francisco 49
Biomed Realty Trust Enters into Agreement with University of California San Diego 50
Galmed Pharma Enters into Agreement with University of California 51
Xcell Biosciences Enters into Partnership with University of California, San Francisco 52
Selvita Enters into Agreement with University of California, San Francisco 53
Natera Enters into Research Agreement with University of California, San Francisco 54
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 55
University of California, Berkeley Enters into Agreement with Aduro Biotech 57
Trethera Enters into Research Agreement with University of California, Los Angeles 58
UCSF Partners with Berkeley Lights 59
NewBio Therapeutics and University of California Los Angeles Enter into Agreement 60
Janssen Pharma Enters into Agreement with University of California, San Diego 61
Bristol-Myers Squibb Enters into Research Agreement with UCLA 62
BioCision Partners with University of California 63
Color Genomics Partners with University of California Health 64
UC San Francisco Enters into Research Agreement with GlaxoSmithKline 65
Novoheart Enters into Research Agreement with University of California Irvine 66
Celgene Partners with Recombinant Antibody Network 67
New York Blood Center Enters into Agreement with University of California 68
AccentCare Forms Joint Venture With UC San Diego Health System 69
Calico Enters into Research Agreement with QB3 70
UCSF Medical Center Forms Joint venture with John Muir Health 71
BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 72
Zymeworks Enters into Research Agreement with University of California, Los Angeles 73
Sutro Biopharma Enters into Agreement with University of California, San Francisco 74
Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 75
Navidea Biopharma Amends Agreement with University of California San Francisco 76
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 77
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 78
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 80
Centers For Therapeutic Innovation Partners with UC San Francisco 81
NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 82
OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 83
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 84
DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 85
University of California Enters Into Research Agreement With Sanofi 86
Licensing Agreements 87
CavoGene LifeSciences Enters into Licensing Agreement with University of California San Diego 87
FUJIFILM Cellular Dynamics Enters into Licensing Agreement with University of California Irvine 88
Bloom Science Enters into Licensing Agreement with UCLA 89
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 90
Excision BioTherapeutics Enters into Licensing Agreement with University of California Berkeley 91
MonTa Biosciences Enters into Licensing Agreement with University of California and Technical University of Denmark 92
Diamyd Medical Enters into Licensing Agreement with University of California 93
Lyceum Pharma Enters into Licensing Agreement with University of California Irvine 94
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 95
CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 96
Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 98
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 99
Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 100
MatriSys Bioscience Enters into Licensing Agreement with University of California, San Diego 101
Kite Pharma Enters into Licensing Agreement with Regents of the University of California 102
Oncternal Therapeutics Enters into Licensing Agreement with University of California 103
Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 104
Pionyr Immunotherapeutics Enters into Licensing Agreement with University of California and University of Toronto 105
Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 106
Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 107
Sage Therapeutics Enters into Licensing Agreement with University of California 108
Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 109
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 110
Novoheart Enters into Licensing Agreement with University of California Davis 111
MiNA Therapeutics Enters into Licensing Agreement with University of California San Francisco 112
Batu Biologics Enters into Licensing Agreement with University of California, San Diego 113
Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 114
Silarus Therapeutics Receives Rights from University of California 115
Dermala Enters into Licensing Agreement with Regents of the University of California 116
Countervail Enters into Licensing Agreement with University of California 117
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 118
Novoheart Enters into Licensing Agreement with University of California Irvine 119
Merganser Biotech Enters into Licensing Agreement with Regents of the University of California 120
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 121
Curtana Pharma Enters into Licensing Agreement with University of California San Diego 122
SomPharma Enters into Licensing Agreement with University of California, San Diego 123
University of California San Francisco Enters into Licensing Agreement with Mitokinin 124
CohBar Enters Into Licensing Agreement With Regents Of The University Of California 125
Abreos Biosciences Enter into License Agreement with University of California San 126
Caribou Biosciences Enters into Licensing Agreement with Regents of the University of California and University of Vienna 127
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 128
Fibrocell Science Enters Into Licensing Agreement With University of California 129
Aduro BioTech Enters into Licensing Agreement with UCB 130
DesignMedix Enters into Licensing Agreement with University of California, San Diego 131
Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 132
PsychoGenics Enters into Licensing Agreement with University of California, San Diego 133
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 134
SeraCare Life Sciences Enters into Licensing Agreement with University of California 135
Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 136
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 137
PaxVax Enters into Licensing Agreement with University Of California, San Diego 138
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 139
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 140
Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 141
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 142
Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 143
Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 144
Islet Sciences Enters Into Licensing Agreement With University of California 145
Equity Offering 146
Antiva Biosciences Spin Out from University of California San Diego 146
Asset Transactions 147
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 147
University of California – Key Competitors 149
University of California – Key Employees 150
University of California – Locations And Subsidiaries 151
Head Office 151
Other Locations & Subsidiaries 151
Recent Developments 153
Legal and Regulatory 153
Sep 10, 2018: CRISPR Therapeutics, Intellia Therapeutics & Caribou Biosciences provide update on US federal circuit decision upholding the ruling by US patent and trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology 153
Government and Public Interest 154
Sep 19, 2018: NIH funds study to prevent, treat HIV among adolescents in poor countries 154
Dec 11, 2017: $5 million grant from NIH will enable UCLA to develop new models for autism 155
Oct 16, 2017: Researchers Show the Potential of Precision Medicine for Treating Rare Cancers 156
Sep 20, 2017: Discovery helps improve accuracy of CRISPR-Cas9 gene editing 157
Sep 20, 2017: Space research institute awards 10 research grants 159
Sep 11, 2017: New University of California Cancer Consortium to tackle state’s second leading cause of death 161
Sep 05, 2017: Zika virus shrinks brain tumours in lab tests 162
Apr 21, 2017: NIH Funds Seven International Centers of Excellence for Malaria Research 163
Mar 15, 2017: UCLA researchers’ finding holds promise for treating children after brain injuries 165
Jan 09, 2017: UCLA to play a leadership role in $21.7M NIH grant for epilepsy research 167
Product News 168
Oct 10, 2017: Allergy Drug Improves Function in Patients with Chronic Injury from Multiple Sclerosis 168
Jul 20, 2017: Immune-Cell Numbers Predict Response to Combination Immunotherapy in Melanoma 170
Other Significant Developments 172
Sep 10, 2018: UC vows to protect groundbreaking CRISPR invention despite court decision 172
Appendix 173
Methodology 173
About GlobalData 173
Contact Us 173
Disclaimer 173

List of Tables
University of California, Pharmaceuticals & Healthcare, Key Facts 2
University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
University of California, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
University of California, Deals By Therapy Area, 2012 to YTD 2018 13
University of California, Medical Devices Deals, 2012 to YTD 2018 15
University of California, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
DNAlite Therapeutics Raises USD1.5 Million in Seed Financing 26
Allogene Therapeutics Raises USD120 Million in Private Financing 28
Akili Interactive Enters into Licensing Agreement with University of California 30
PharmaResearch Products Enters into Agreement with University of California 31
Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 32
InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 33
Helperby Therapeutics Enters into Collaboration Agreement with University of California Los Angeles 34
OncoSec Medical Enters into Research Agreement with University of California 35
Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 36
Protagen Enters into Agreement with University of California, San Francisco 37
INSYS Therapeutics Expands Agreement with University of California San Diego 38
Clerisy Enters into Partnership with University of California 39
Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 40
MYOS RENS Technology Enters into Research Agreement with University Of California Berkley 41
Fate Therapeutics Enters into Partnership with University of California San Diego 42
Apexigen Enters into Agreement with University of California San Francisco 43
Strata Oncology Enters into Agreement with University of California 44
Novartis Enters into Agreement with University of California 45
BrainStorm Cell Therapeutics Enters into Agreement with University of California Irvine Medical Center 46
ShangPharma Innovation Enters into Partnership with the University of California San Francisco 47
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 48
Xynomic Pharma Enters into Agreement with University of California San Francisco 49
Biomed Realty Trust Enters into Agreement with University of California San Diego 50
Galmed Pharma Enters into Agreement with University of California 51
Xcell Biosciences Enters into Partnership with University of California, San Francisco 52
Selvita Enters into Agreement with University of California, San Francisco 53
Natera Enters into Research Agreement with University of California, San Francisco 54
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 55
University of California, Berkeley Enters into Agreement with Aduro Biotech 57
Trethera Enters into Research Agreement with University of California, Los Angeles 58
UCSF Partners with Berkeley Lights 59
NewBio Therapeutics and University of California Los Angeles Enter into Agreement 60
Janssen Pharma Enters into Agreement with University of California, San Diego 61
Bristol-Myers Squibb Enters into Research Agreement with UCLA 62
BioCision Partners with University of California 63
Color Genomics Partners with University of California Health 64
UC San Francisco Enters into Research Agreement with GlaxoSmithKline 65
Novoheart Enters into Research Agreement with University of California Irvine 66
Celgene Partners with Recombinant Antibody Network 67
New York Blood Center Enters into Agreement with University of California 68
AccentCare Forms Joint Venture With UC San Diego Health System 69
Calico Enters into Research Agreement with QB3 70
UCSF Medical Center Forms Joint venture with John Muir Health 71
BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 72
Zymeworks Enters into Research Agreement with University of California, Los Angeles 73
Sutro Biopharma Enters into Agreement with University of California, San Francisco 74
Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 75
Navidea Biopharma Amends Agreement with University of California San Francisco 76
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 77
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 78
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 80
Centers For Therapeutic Innovation Partners with UC San Francisco 81
NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 82
OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 83
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 84
DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 85
University of California Enters Into Research Agreement With Sanofi 86
CavoGene LifeSciences Enters into Licensing Agreement with University of California San Diego 87
FUJIFILM Cellular Dynamics Enters into Licensing Agreement with University of California Irvine 88
Bloom Science Enters into Licensing Agreement with UCLA 89
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 90
Excision BioTherapeutics Enters into Licensing Agreement with University of California Berkeley 91
MonTa Biosciences Enters into Licensing Agreement with University of California and Technical University of Denmark 92
Diamyd Medical Enters into Licensing Agreement with University of California 93
Lyceum Pharma Enters into Licensing Agreement with University of California Irvine 94
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 95
CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 96
Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 98
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 99
Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 100
MatriSys Bioscience Enters into Licensing Agreement with University of California, San Diego 101
Kite Pharma Enters into Licensing Agreement with Regents of the University of California 102
Oncternal Therapeutics Enters into Licensing Agreement with University of California 103
Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 104
Pionyr Immunotherapeutics Enters into Licensing Agreement with University of California and University of Toronto 105
Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 106
Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 107
Sage Therapeutics Enters into Licensing Agreement with University of California 108
Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 109
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 110
Novoheart Enters into Licensing Agreement with University of California Davis 111
MiNA Therapeutics Enters into Licensing Agreement with University of California San Francisco 112
Batu Biologics Enters into Licensing Agreement with University of California, San Diego 113
Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 114
Silarus Therapeutics Receives Rights from University of California 115
Dermala Enters into Licensing Agreement with Regents of the University of California 116
Countervail Enters into Licensing Agreement with University of California 117
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 118
Novoheart Enters into Licensing Agreement with University of California Irvine 119
Merganser Biotech Enters into Licensing Agreement with Regents of the University of California 120
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 121
Curtana Pharma Enters into Licensing Agreement with University of California San Diego 122
SomPharma Enters into Licensing Agreement with University of California, San Diego 123
University of California San Francisco Enters into Licensing Agreement with Mitokinin 124
CohBar Enters Into Licensing Agreement With Regents Of The University Of California 125
Abreos Biosciences Enter into License Agreement with University of California San 126
Caribou Biosciences Enters into Licensing Agreement with Regents of the University of California and University of Vienna 127
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 128
Fibrocell Science Enters Into Licensing Agreement With University of California 129
Aduro BioTech Enters into Licensing Agreement with UCB 130
DesignMedix Enters into Licensing Agreement with University of California, San Diego 131
Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 132
PsychoGenics Enters into Licensing Agreement with University of California, San Diego 133
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 134
SeraCare Life Sciences Enters into Licensing Agreement with University of California 135
Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 136
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 137
PaxVax Enters into Licensing Agreement with University Of California, San Diego 138
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 139
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 140
Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 141
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 142
Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 143
Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 144
Islet Sciences Enters Into Licensing Agreement With University of California 145
Antiva Biosciences Spin Out from University of California San Diego 146
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 147
University of California, Key Competitors 149
University of California, Key Employees 150
University of California, Subsidiaries 151

List of Figures
University of California, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
University of California, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
University of California, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 11
University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
University of California, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
University of California, Medical Devices Deals, 2012 to YTD 2018 15

★海外企業調査レポート[University of California：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • AstraZeneca PLC：企業のM&A・事業提携・投資動向
    AstraZeneca PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AstraZeneca PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Raytheon Co：戦略・SWOT・企業財務分析
    Raytheon Co - Strategy, SWOT and Corporate Finance Report Summary Raytheon Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • F. Hoffmann-La Roche Ltd (ROG)：企業の財務・戦略的SWOT分析
    F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Semiconductor Manufacturing International Corporation
    Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report Summary Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Cimab SA-製薬・医療分野：企業M&A・提携分析
    Summary Cimab SA (Cimab) is a biopharmaceutical company that develops and markets monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other diseases related to the immune system. The company offers products such as cimaher nimotuzumab, ior epocim epoeti …
  • PureCircle Ltd：企業の戦略・SWOT・財務情報
    PureCircle Ltd - Strategy, SWOT and Corporate Finance Report Summary PureCircle Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Bulova Technologies Group, Inc.：戦略・SWOT・企業財務分析
    Bulova Technologies Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bulova Technologies Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Proteus Digital Health Inc-医療機器分野：企業M&A・提携分析
    Summary Proteus Digital Health Inc (Proteus) is a medical device company which develops and sells digital medicine for chronic diseases through in-house research and through partnership with the pharmaceutical, medical device and biotechnology companies. Its flagship product, Proteus Discover digita …
  • Zoll Medical Corporation-医療機器分野：企業M&A・提携分析
    Summary ZOLL Medical Corporation (Zoll), a subsidiary of Asahi Kasei Corporation, is a provider of medical devices and software solutions for advance emergency care. The company designs, manufactures and markets resuscitation devices and systems used for resuscitation and acute critical care victims …
  • Harmony Gold Mining Co Ltd：企業の戦略・SWOT・財務情報
    Harmony Gold Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Harmony Gold Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Rekah Pharmaceutical Industry Ltd (REKA)：企業の財務・戦略的SWOT分析
    Rekah Pharmaceutical Industry Ltd (REKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • s.a. D’leteren n.v.：企業の戦略・SWOT・財務情報
    s.a. D'leteren n.v. - Strategy, SWOT and Corporate Finance Report Summary s.a. D'leteren n.v. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • PT Hexindo Adiperkasa Tbk：企業の戦略・SWOT・財務分析
    PT Hexindo Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Hexindo Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Tampa Electric Co：企業の発電所・SWOT分析2018
    Tampa Electric Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Total Petrochemicals & Refining USA Inc：企業の戦略的SWOT分析
    Total Petrochemicals & Refining USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Avery Dennison Corporation (AVY)：企業の財務・戦略的SWOT分析
    Avery Dennison Corporation (AVY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • OrthoPediatrics Corp (KIDS)：医療機器：M&Aディール及び事業提携情報
    Summary OrthoPediatrics Corp (OrthoPediatrics) is a medical device company that designs, develops and distributes implants and instruments. The company offers trauma and deformity, spine, sports medicine, and clinical education products. It provides cannulated screws, spine system, ACL reconstructio …
  • Belvedere International Inc.：企業の戦略・SWOT・財務情報
    Belvedere International Inc. - Strategy, SWOT and Corporate Finance Report Summary Belvedere International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • WntResearch AB (WNT)：製薬・医療：M&Aディール及び事業提携情報
    Summary WntResearch AB (WntResearch) is a biotechnology company that develops novel anti-metastatic therapies for the treatment of cancer. The company's development stage products include Foxy-5 and Box-5. Its lead project, Foxy-5, a peptide which is in Phase I clinical development for reconstitutin …
  • MakeMyTrip Limited：企業のM&A・事業提携・投資動向
    MakeMyTrip Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MakeMyTrip Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆